We conducted a comprehensive analysis to ascertain the precise prognostic implications of CD9 in B-ALL, initially examining its correlation with clinical and biological variables in 3,006 CD9+ and 389 CD9– patients (Table 1). The gene discussed is CD9; the disease is precursor B-cell acute lymphoblastic leukemia.